Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells 5,760 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 5,760 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $20.81, for a total transaction of $119,865.60. Following the completion of the transaction, the insider now owns 19,838 shares of the company’s stock, valued at approximately $412,828.78. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Christine Ring also recently made the following trade(s):

• On Wednesday, June 12th, Christine Ring sold 1,900 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.01, for a total transaction of $32,319.00.
• On Wednesday, June 5th, Christine Ring sold 400 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.00, for a total transaction of $6,800.00.
• On Monday, June 3rd, Christine Ring sold 1,596 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.01, for a total transaction of $27,147.96.

Nurix Therapeutics Trading Up 2.5 %

Shares of NASDAQ NRIX opened at $19.41 on Thursday. Nurix Therapeutics, Inc. has a 12 month low of $4.22 and a 12 month high of $22.44. The company has a 50-day simple moving average of $16.15 and a 200-day simple moving average of $13.09.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Wednesday, April 10th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.04. The business had revenue of $16.59 million during the quarter, compared to the consensus estimate of $14.58 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. As a group, analysts expect that Nurix Therapeutics, Inc. will post -2.85 EPS for the current year.

Institutional Investors Weigh In On Nurix Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. ProShare Advisors LLC grew its holdings in shares of Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after buying an additional 998 shares in the last quarter. Public Employees Retirement System of Ohio grew its holdings in shares of Nurix Therapeutics by 3.7% during the first quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock worth $747,000 after buying an additional 1,820 shares in the last quarter. Raymond James & Associates boosted its position in shares of Nurix Therapeutics by 3.1% in the fourth quarter. Raymond James & Associates now owns 101,006 shares of the company’s stock worth $1,042,000 after acquiring an additional 3,018 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Nurix Therapeutics by 299.8% in the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after acquiring an additional 3,424 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Nurix Therapeutics by 67.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after acquiring an additional 3,793 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on NRIX shares. HC Wainwright increased their price target on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, June 18th. Stephens started coverage on shares of Nurix Therapeutics in a report on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 price target for the company. Robert W. Baird raised their target price on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a report on Thursday, April 11th. JPMorgan Chase & Co. raised their target price on shares of Nurix Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, June 17th. Finally, Stifel Nicolaus restated a “buy” rating and set a $27.00 target price on shares of Nurix Therapeutics in a report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $25.10.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.